Patents Assigned to AUCENTRA THERAPEUTICS PTY LTD
  • N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds
    Patent number: 11970491
    Abstract: A novel class of inhibitors of protein kinates that are useful in the treatment of cell proliferative diseases and conditions, and especially those characterised by over-expression of CDK4, CDK6 and/or cyclin D, including certain cancers of lung, breast, brain, central nervous system, colorectal cancer and leukaemias.
    Type: Grant
    Filed: August 31, 2021
    Date of Patent: April 30, 2024
    Assignee: AUCENTRA THERAPEUTICS PTY LTD
    Inventors: Shudong Wang, Solomon Tadesse Zeleke, Mingfeng Yu
  • Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents
    Patent number: 11111245
    Abstract: A novel class of inhibitors of protein kinases that are useful in the treatment of cell proliferative diseases and conditions, and especially those characterised by over-expression of one or more CDK enzyme and/or by one or more aberrant CDK activity, including certain cancers of lung, breast, brain, ovary, prostate, colorectal cancer and leukaemias. The inhibitors have the general structure (I).
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: September 7, 2021
    Assignee: Aucentra Therapeutics Pty Ltd
    Inventors: Shudong Wang, Sarah Al Haj Diab, Yi Long
  • N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds
    Patent number: 10479785
    Abstract: A novel class of inhibitors of protein kinases that are useful in the treatment of cell proliferative diseases and conditions, and especially those characterised by over-expression of CDK4, CDK6 and/or cyclin D, including certain cancers of lung, breast, brain, central nervous system, colorectal cancer and leukaemias.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: November 19, 2019
    Assignee: AUCENTRA THERAPEUTICS PTY LTD
    Inventors: Shudong Wang, Solomon Tadesse Zeleke, Mingfeng Yu
  • N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds
    Patent number: RE49850
    Abstract: A novel class of inhibitors of protein kinases that are useful in the treatment of cell proliferative diseases and conditions, and especially those characterised by over-expression of CDK4, CDK6 and/or cyclin D, including certain cancers of lung, breast, brain, central nervous system, colorectal cancer and leukaemias.
    Type: Grant
    Filed: February 2, 2022
    Date of Patent: February 27, 2024
    Assignee: AUCENTRA THERAPEUTICS PTY LTD
    Inventors: Shudong Wang, Solomon Tadesse Zeleke, Mingfeng Yu